URGN

29.7686.18%
AS

Arie S. Belldegrun

Co-Founder & Executive Chairman

Dr. Arie S. Belldegrun, F.A.C.S., M.D., serves as the Member of Scientific Advisory Board at Breakthrough Services, LLC. He is Founder of Vida Ventures Advisors, LLC, where he also serves as Senior Managing Director since November 2017. He is Co-Founder of Allogene Therapeutics, Inc. and also serves as Executive Chairman since November 2017. Dr. Belldegrun serves as Independent Chairman of UroGen Pharma Ltd. since December 2012, having joined the company in December 2002. He serves as Chairman of Arno Therapeutics, Inc., which he joined in March 2008. He serves as Partner and Chairman of Two River Group Holdings, LLC since June 2009, where he is also a Member of the Advisory Board. He serves as Chairman of Bellco Capital LLC since 2004. He serves as Co-chairman of Symbiotic Capital since June 2023. He serves as Co-chairman of Breakthrough Properties since April 2019 and serves on the board of Breakthrough Services LLC since April 2019. He is a Director of Cell Design Labs, Inc., a Director of Pontifax Venture Capital, and a Director of ByHeart, Inc. since October 2019. He is Co-Owner of Vecchia Partners, Ltd. and Co-Owner of Bellco Legacy Ii Trust. He is Co-Founder of 76Bio, Inc. He serves as Advisor of Eight Partners VC, LLC. He is Co-Founder and a board member of the California Institute for Immunology & Immunotherapy. At the David Geffen School of Medicine at the University of California, Los Angeles, which he joined in October 1988, he is a Research Professor, holds the Roy and Carol Doumani Chair in Urologic Oncology, and serves as Director of the Institute of Urologic Oncology. Previously, Dr. Belldegrun was Independent Chairman of the Board of Kronos Bio, Inc. from November 2017 to June 2025. He was an Independent Director of Ginkgo Bioworks Holdings, Inc. from September 2021 to November 7, 2024. He is Founder of Kite Pharma, Inc., where he also served as Chairman, President and Chief Executive Officer from March 2014 to October 2017, and as a Director from June 2009 to October 2017. He served as Director at Teva Pharmaceutical Industries Limited, where he was employed from February 5, 2013 to January 26, 2017. He served as Director at Capricor Therapeutics, Inc., where he was employed until November 20, 2013. He served as Director at Talon Therapeutics, Inc., where he was employed from April 2004 to December 31, 2009. He served as Director at Nile Therapeutics, Inc., which he joined on September 24, 2009. He served as Director at SonaCare Medical, LLC, which he joined in September 2009. He is Founder of Cougar Biotechnology, Inc. and also served as Chairman of the Scientific Advisory Board, where he was employed from December 2003 to July 2009. He served as Director at Chem Rx Corporation, where he was employed from June 1, 2005 to January 2008. He is Founder of Agensys, Inc. and also served as Chairman. He was Chairman of the Medical Advisory Board for RENCAREX of Heidelberg Pharma AG. He served as Director of IconOVir Bio, Inc. He was a research fellow in surgical oncology and immunotherapy at the National Cancer Institute/NIH from July 1985 to August 1988. Dr. Belldegrun has several years' experience in science, medicine, and company formation, has authored several books on oncology, and numerous scientific and medical papers. Dr. Belldegrun holds a B.S. from Hebrew University Faculty of Medicine, an M.D. from Hebrew University Faculty of Medicine, and a Master's in Immunology from Weizmann Institute of Science. He completed his residency in urologic surgery at Harvard Medical School.

Positions